Actavis Launches Generic Temovate Cream
Actavis has launched the generic version of Fougera's clobetasol propionate cream 0.05% (Temovate)
Actavis has launched the generic version of Fougera’s clobetasol propionate cream 0.05% (Temovate), a high-potency topical formulation designed to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults.
Over a 12-month period ending on January 15, 2015, Temovate generated total US brand and generic sales of approximately $185 million, according to IMS Health.
The preparation contains clobetasol propionate, a synthetic corticosteroid for topical dermatologic use. The FDA warns that Temovate should not be used beyond 2 consecutive weeks, as the drug has the potential to suppress the hypothalamic-pituitary-adrenal axis.
The only adverse effect observed in patients who have used Temovate is a burning sensation at the application area.